CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• OP. Inc. Y/Y Annual
Regencell Bioscience Holdings Limited  (NASDAQ: RGC)
 

RGC's Operating Income Growth by Quarter and Year

Regencell Bioscience Holdings Limited's Operating Income results by quarter and year

Download as CSV




RGC Operating Income (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -3.77 -6.27 -7.62 -1.38
3rd Quarter September 0.00 0.00 0.00 0.00
2nd Quarter June 0.00 0.00 0.00 0.00
1st Quarter March 0.00 0.00 0.00 0.00
FY   -3.77 -6.27 -7.62 -1.38

RGCs Annual Operating Income
Regencell Bioscience Holdings Limited's Operating Income in the fiscal year 2025 $ -3.77 millions
Regencell Bioscience Holdings Limited's Operating Income in the fiscal year 2023 $ -6.27 millions
Regencell Bioscience Holdings Limited's Operating Income in the fiscal year 2022 $ -7.62 millions
Regencell Bioscience Holdings Limited's Operating Income in the fiscal year 2021 $ -1.38 millions
Regencell Bioscience Holdings Limited's Operating Income in the fiscal year 2017 $ 271.70 millions




RGC Operating Income fourth quarter 2025 Y/Y Growth Comment
Regencell Bioscience Holdings Limited in the fourth quarter 2025 recorded Operating Loss of $ -3.77 millions.

According to the results reported in the fourth quarter 2025, Regencell Bioscience Holdings Limited achieved the best Operating Income growth in Legal Cannabis industry. While Regencell Bioscience Holdings Limited' s Operating Income no change of 0% ranks overall at the positon no. in the fourth quarter 2025.

Explain Operating Income growth


RGC Operating Income ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Regencell Bioscience Holdings Limited's fourth quarter 2025 Operating Income $ -3.77 millions RGC's Income Statement
Regencell Bioscience Holdings Limited's fourth quarter 2024 Operating Income $ -6.27 millions Quarterly RGC's Income Statement


RGC Operating Income (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Compare RGC Profitability >> Back to RGC Growth rate Comparisons >>


Operating Income fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Regencell Bioscience Holdings Limited's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGC's IV. Quarter Q/Q Operating Income Comment


Operating Income Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGC's IV. Quarter Q/Q Operating Income Comment


Regencell Bioscience Holdings Limited's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
0		 12 Months Ending
0		 12 Months Ending
0
Cumulative Operating Income 12 Months Ending $ -3.77 $ -6.27 $ 0.00 $ 0.00 $ 0.00
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #


Cumulative Operating Income growth Comment


Regencell Bioscience Holdings Limited achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment


Regencell Bioscience Holdings Limited achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Operating Income Growth
Legal Cannabis Industry Operating Income Growth Trends and Statistics
Consumer Non Cyclical Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RGC's Operating Income Growth Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth




Companies with similar Operating Income no change for the quarter ending Jun 30 2025 within Consumer Non Cyclical SectorY/Y Change %Operating Income for the quarter ending Jun 30 2025


About Regencell Bioscience Holdings Limited Operating Income Growth Rates (RGC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.